We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Cobra Bio-Man. | LSE:CBF | London | Ordinary Share | GB0031704835 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.25 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
07/4/2009 09:02 | Does anyone have a 'fair' valuation assumption as a comparitive to the current £2 million market cap ? | imabastard | |
07/4/2009 08:21 | ORT-VAC also has very large potential value, the recent success of ORT-VAC as shown by the RNS the other day, could be the another reason we have an approach | hyper al | |
07/4/2009 08:16 | jdb, think before typing! I worked in validation, I know how much it costs to validate equipment. My point was that the value of the equipment, training staff, implementing procedures, validating those procedures....would most likely be well over the current market cap. While each specific new product and related processes would need specific validation, buying Cobra would seem a cheap way of setting up a pilot plant for certain companies. Location would be an issue, but still, transporting it and setting up again would still strike me as a quick and easy option. Jdb2005 - 7 Apr'09 - 08:20 - 4182 of 4198 d*c - you do talk some rubbish sometimes - their plants are fully validated otherwise they would not have contracts to produce vaccines etc. Don't attempt to short these !!! Hyper Al - 7 Apr'09 - 08:23 - 4183 of 4198 Jdb2005 I think he means validating as in valuation of plant would mean that it would cost a couple of £m to buy | the_doctor | |
07/4/2009 08:09 | If they chose to sell off the contents of the company, but not the limited quoted shell, would anybody object then ? | c2b | |
07/4/2009 08:06 | Hyper - Mr & Mrs Dixon are the majority holders then. | jdb2005 | |
07/4/2009 08:04 | Thats right. | bones30 | |
07/4/2009 07:58 | I think we are up 46% not the 110% advfn suggests | hyper al | |
07/4/2009 07:56 | Jdb2005 This is from cobra website, you can tell they are in serious discussions as this info was updated on their website on 6 April Mr & Mrs Dixon 43.9% 19,450,000 Pershing Keen Nominees 6.7% 2,983,500 Chase Nominees 6.6% 2,931,675 Vidacos Nominees 5.9% 2,615,213 Cavendish Asset Management 5.1% 2,272,000 Lynchwood Nominees 3.6% 1,590,000 Also Peter Fothergill 0.7% 326,000 Peter Coleman 0.6% 280,000 Simon Saxby 0.6% 260,000 David Thatcher 0.4% 196,500 Michael Gatenby 0.3% 160,000 Prof Nigel Slater 0.3% 139,000 David Oxlade 0.3% 130,000 | hyper al | |
07/4/2009 07:51 | Hyper - when there is talk of potential bid you start looking at who are the majority shareholders in a company. Cobra will not be sold off cheaply. | jdb2005 | |
07/4/2009 07:47 | C2B I agree some long term holders may suffer. But at this price it is a bargain It happened recently with my investment in Stem. It was sold at a very low price, well at near SP, on the grounds that it was the best thing for the business and employees | hyper al | |
07/4/2009 07:47 | Lets give him the benefit of doubt - as a going concern Cobra must be worth several times its present low valuation. | jdb2005 | |
07/4/2009 07:43 | Who is prepared to make a "fuss" if a deal, if one does come, turns out not to benefit all shareholders equally ??? This company has a bad track record on fair dealing. | c2b | |
07/4/2009 07:43 | pegasus59 I think you should at the very least break even. I have held a share in this for years, yep 1 share. Kept in error. purchased quite a few as soon as I could today. We must not forget that the staff are also a major asset in this company. | hyper al | |
07/4/2009 07:34 | Jdb - If you read the_doctor again you will realise that is exactly what he meant - i.e. a validated operating plant is worth much more than its bald cost of construction. | boadicea | |
07/4/2009 07:33 | Think this should be at least around the 10p level, 8p at lowest. | hyper al | |
07/4/2009 07:27 | current market cap £1.88m Think it will be way above that, just for the manufacturing facility, add their business and this is way undervalued! | hyper al | |
07/4/2009 07:23 | Jdb2005 I think he means validating as in valuation of plant would mean that it would cost a couple of £m to buy | hyper al | |
07/4/2009 07:20 | d*c - you do talk some rubbish sometimes - their plants are fully validated otherwise they would not have contracts to produce vaccines etc. Don't attempt to short these !!! | jdb2005 | |
07/4/2009 07:12 | It has always been undervalued. Just validating the plant would cost a couple of £m! | the_doctor | |
07/4/2009 07:08 | Cobra note about talks with third party re potential bid for the company shows how undervalued it has become. | jdb2005 | |
07/4/2009 07:01 | They should have been in talks with a third party for years IMO, given looking for a buyer has always been an obvious option. | the_doctor | |
07/4/2009 06:56 | what is the companies current cash position? | hyper al | |
07/4/2009 06:53 | pmsl - you too have been noted.. | whowantstobeamillionaire |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions